An interventional study of Survey Administration and Electronic Health Record Review in Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Fred Hutchinson Cancer Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical trial will evaluate the feasibility, acceptability, and potential efficacy of a palliative care pharmacist-led group telehealth opioid education session for palliative care patients prescribed opioids for cancer-related pain. While opioids are commonly used in palliative care settings to manage cancer-related pain, their significant side effects, complicated administration requirements, and concerns about addiction can make it challenging for patients to use opioids safely and effectively. Some patients may even avoid opioids altogether because of these concerns, even when opioids are clinically indicated, leading to poor symptom control. To address these challenges, a telehealth education session was developed as a clinical initiative by a palliative care pharmacist, addressing safe and effective opioid management. Educational priorities and session content were informed by a survey of interdisciplinary palliative care clinicians that identified barriers and facilitators to opioid education and key patient educational needs. Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. This study will assess the feasibility and acceptability of delivering the intervention, as well as its preliminary effects on opioid knowledge and self-efficacy. If feasible and acceptable, this pharmacist-led telehealth education model could represent a scalable strategy to improve opioid management for patients with cancer-related pain.
OUTLINE:
Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content.
After attending the pharmacist education session, participants will complete the final survey within 1 month, concluding their participation.
Fred Hutchinson Cancer Center is the lead sponsor of 547 studies on the registry; 79 are open to participants now.
Of its 59 completed or terminated interventional studies of FDA-regulated products, 46 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content.
Other: Survey Administration · Other: Electronic Health Record Review
Ancillary studies - pre- and post-session surveys to assess opioid knowledge and self-efficacy, and post-session to assess session acceptability
Ancillary studies
Percentage of referred patients who attend pharmacist education session (Feasibility)
Feasibility of the pharmacist education session will be interpreted as an overall session attendance-to-referral rate ≥ 50%.
Time frame: Up to 6 months
Participant score on the "general acceptability" item of the Theoretical Framework of Acceptability questionnaire
Assessed on post-session surveys, delivered within 7 days after session attendance, with up to one month of follow-up to encourage survey completion. Acceptability of the pharmacist education session will be interpreted as \> 70% respondents rating the sessions as ≥ 4/5 (i.e. "acceptable" or "completely acceptable") on the "general acceptability" item of the Theoretical Framework of Acceptability scale (5 point Likert scale), assessed on the post-session survey.
Time frame: Up to 1 month post-session
Plan to share: Yes — This study will generate quantitative and qualitative human subjects data as part of a pilot evaluation of a palliative care pharmacist-led group telehealth opioid education session intervention for patients with cancer pain. Quantitative data will include structured survey responses and electronic health record data. The shared data package will include de-identified quantitative datasets, qualitative data files where appropriate, data dictionaries/codebooks, and copies of study instruments, subject to instrument licensing requirements. De-identified datasets will be preserved and shared via a suitable repository that supports health-related research data, such as a general-purpose repository (e.g., Dryad or Figshare) or an institutional repository supported by Fred Hutchinson Cancer Center. The selected repository will provide persistent identifiers (e.g., DOIs) to support citation and long-term access.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be made available no later than the time of publication of the primary study results or within 12 months of completion of the project period, whichever occurs first.
Access criteria: Shared data will be made available with minimal access restrictions, consistent with protecting participant privacy and honoring informed consent. Data will be licensed to permit reuse for non-commercial research purposes, including secondary analyses, methodologic studies, and meta-analyses, with appropriate citation of the original dataset and investigators. Users of the data will be required to acknowledge the data source in publications and presentations. No attempt will be made to re-identify study participants, and no data will be shared that could reasonably place participants at risk of deductive disclosure.
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Jul 2027, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fred Hutchinson Cancer Center →